Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
121nexus is a digital health company that provides a specialized SaaS platform for the medical device and pharmaceutical industries. The platform enables manufacturers to manage and distribute critical product information, such as electronic Instructions for Use (eIFU) and regulatory data, through a single point of truth linked to physical products via QR codes. By automating compliance with global Unique Device Identification (UDI) requirements, 121nexus helps companies reduce labeling costs and improve patient safety. The company's technology also facilitates anti-counterfeiting measures and enhances patient engagement by providing direct access to up-to-date product resources. In May 2022, 121nexus was acquired by Reed Tech, a LexisNexis company, to integrate its capabilities into a broader suite of life sciences regulatory solutions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on 121nexus.